Scientists have uncovered the first evidence of Alzheimer's disease transmission in living individuals, marking a significant ...

A method for slowing disease progress in Alzheimer's patients may also delay onset in people predisposed to the disease who ...

Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression of symptoms in people with early-onset Alzheimer's.

A comprehensive Thought Leaders Invited Review in Brain Medicine highlights the crucial role of CD2-associated protein (CD2AP ...

Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to ...

A protein that impacts Alzheimer’s disease offers new opportunities for targeted treatments, although its cell-specific ...

“This follow-up study of gantenerumab, an anti-amyloid drug that previously failed to slow cognitive decline in people at risk of Alzheimer’s disease, suggests that extended use of anti-amyloid ...

and Joanne Knight Distinguished Professor of Neurology at WashU Medicine, is the study director of an international clinical trial that finds an anti-amyloid drug can delay the onset of cognitive ...

A new study suggests a promising alternative to previous attempts to remove the sticky, toxic amyloid beta plaques from brains with Alzheimer's Disease: enhancing the brain's own immune cells to clear ...